Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 67
Filter
1.
J Am Med Inform Assoc ; 6(5): 420-7, 1999.
Article in English | MEDLINE | ID: mdl-10495101

ABSTRACT

PURPOSE: This study examines how the information provided by a diagnostic decision support system for clinical cases of varying diagnostic difficulty affects physicians' diagnostic performance. METHODS: A national sample of 67 internists, 35 family physicians, and 6 other physicians used the Quick Medical Reference (QMR) diagnostic decision support system to assist them in the diagnosis of written clinical cases. Three sets of eight cases, stratified by diagnostic difficulty and the potential of QMR to produce high-quality information, were used. The effects of using QMR on three measures of physicians' diagnostic performance were analyzed using analyses of variance. RESULTS: Physicians' diagnostic performance was significantly higher (p < 0.01) on the easier cases and the cases for which QMR could provide higher-quality information. CONCLUSIONS: Physicians' diagnostic performance can be strongly influenced by the quality of information the system produces and the type of cases on which the system is used.


Subject(s)
Decision Support Systems, Clinical , Diagnosis, Computer-Assisted , Analysis of Variance , Clinical Competence , Evaluation Studies as Topic , Expert Systems , Humans , Physicians/standards
2.
J Infect Dis ; 179 Suppl 2: S360-5, 1999 Mar.
Article in English | MEDLINE | ID: mdl-10081508

ABSTRACT

The members of the Interplanetary Society (Pus Club) have made significant contributions to the understanding of the pathogenesis of infective endocarditis (IE). Although the incidence of IE has essentially remained unchanged, the spectrum and characteristics of patients potentially affected by this disorder are expanding. Moreover, in addition to the typical microorganisms implicated in IE, there are increasing reports of new or atypical pathogens causing IE, including those that are resistant to standard antibiotic therapy. The infectious diseases community is challenged to continue to provide effective antimicrobial regimens for IE and to further develop diagnostic and surgical strategies to identify and treat patients with this disorder. New information is available regarding the demographics, diagnostic methods, and therapeutic options for the management of IE.


Subject(s)
Endocarditis, Bacterial , Animals , Anti-Bacterial Agents/therapeutic use , Drug Resistance, Microbial , Endocarditis, Bacterial/diagnosis , Endocarditis, Bacterial/etiology , Endocarditis, Bacterial/therapy , Heart Valve Diseases/complications , Heart Valve Diseases/surgery , Heart Valve Prosthesis/adverse effects , Humans
3.
Cardiol Clin ; 14(3): 351-62, 1996 Aug.
Article in English | MEDLINE | ID: mdl-8853130

ABSTRACT

The epidemiology of IE has evolved over the past 50 years. Mitral valve prolapse and degenerative valvular disease have replaced rheumatic heart disease as the most common predisposing conditions. The average age of patients with IE has increased, and nosocomially acquired cases are becoming more common. Although viridans streptococci are currently responsible for a smaller proportion of cases than previously, this group of bacteria remains the most common cause of prosthetic value and native valve endocarditis. Staphylococci are the most important cause in some community hospitals, in nosocomial IE, and in IVDUs. IE is a multisystem disease, and patients may present with diverse clinical features. In the absence of direct histopathologic and microbiologic examination of valvular vegetations, the diagnosis of IE depends on the detection of endocardial abnormalities and the isolation of a pathogen from blood. Blood culture remains the most important laboratory test and yields the causative microorganism in 95% of patients. Echocardiography has become an important tool for detecting endocardial lesions. The clinical features of IE in IVDUs are somewhat different than those in other populations. The microbiology is distinctive, and right-sided involvement with septic pulmonary emboli is the most common clinical scenario in this group.


Subject(s)
Endocarditis, Bacterial/etiology , Gram-Negative Bacterial Infections/etiology , Gram-Positive Bacterial Infections/etiology , Mycoses/etiology , Endocarditis, Bacterial/diagnosis , Endocarditis, Bacterial/epidemiology , Gram-Negative Bacterial Infections/diagnosis , Gram-Negative Bacterial Infections/epidemiology , Gram-Positive Bacterial Infections/diagnosis , Gram-Positive Bacterial Infections/epidemiology , Humans , Incidence , Mycoses/diagnosis , Mycoses/epidemiology , Prevalence , Risk Factors
4.
Cardiol Clin ; 14(3): 437-50, 1996 Aug.
Article in English | MEDLINE | ID: mdl-8853135

ABSTRACT

The complications of IE may involve any organ system. Cardiac complications are frequently present, and heart failure remains a leading cause of death. Abscess formation in the surrounding cardiac tissues may result in myocardial or pericardial disease, and cardiac conduction abnormalities may develop. Extracardiac complications, including neurologic, vascular, and renal diseases, are also common and are usually caused by either embolization of vegetations or deposition of immune complexes. Despite many advancements in the detection and treatment of the complications of IE, management of these problems remains a challenging endeavor.


Subject(s)
Brain Diseases/etiology , Endocarditis, Bacterial/complications , Heart Diseases/etiology , Vascular Diseases/etiology , Brain Diseases/classification , Heart Diseases/classification , Humans , Vascular Diseases/classification
5.
J Immunol ; 156(6): 2309-15, 1996 Mar 15.
Article in English | MEDLINE | ID: mdl-8690922

ABSTRACT

Deficiency of the sixth component of complement (C6D) is frequently associated with recurrent neisserial infections, especially meningitis caused by Neisseria meningitidis. We here report the molecular bases of C6D in two unrelated subjects, one African American (case 1) and the other Japanese (case 2). Screening all 17 exons of the C6 gene and their boundaries by exon-specific PCR/single strand conformation polymorphism demonstrated aberrant single stranded DNA fragments in exon 12 of case 1 and exon 2 of case 2. Nucleotide sequencing of the amplified DNA fragments revealed a homozygous single-base deletion (G1936) in exon 12 case 1 and a heterozygous single base deletion (C291/C292/C293/C294) in exon 2 of case 2. Both mutations resulted in frame shifts and premature termination of the C6 polypeptide. Sequence-specific oligonucleotide probe hybridization and direct sequencing of exon 12 amplified from genomic DNA further supported the homozygosity of the mutation in case 1. Case 2 is apparently compound heterozygote, but the putative mutation in the other allele of the C6 gene remains unknown. Both case 1 and case 2 were homozygous for the C6A allotype. These data indicate that at least three distinct mutational events can cause C6D, single nucleotide deletions in exons 2 and 12, and a mutation yet unidentified. Thus, similar to other complement protein deficiencies, the pathogenesis of C6D appears to be heterogeneous.


Subject(s)
Complement C6/deficiency , Immunologic Deficiency Syndromes/genetics , Adult , Amino Acid Sequence , Asian People , Base Sequence , Black People/genetics , Complement C6/genetics , Complement C6/isolation & purification , DNA/isolation & purification , Exons/immunology , Humans , Male , Middle Aged , Molecular Sequence Data , Mutation , Polymerase Chain Reaction , Polymorphism, Genetic/immunology , Polymorphism, Single-Stranded Conformational
6.
Infect Dis Clin North Am ; 9(3): 687-713, 1995 Sep.
Article in English | MEDLINE | ID: mdl-7490439

ABSTRACT

Many of the antimicrobial agents described here exhibit great advances over older drugs in terms of antimicrobial spectrum, clinical utility, and, sometimes, safety. The newer cephalosporins are useful for treatment of many common outpatient and inpatient infections. Aztreonam provides excellent coverage against a broad range of aerobic gram-negative bacteria, without the toxicity associated with aminoglycosides. Imipenem exhibits activity against an impressive array of pathogens. These antimicrobials are expensive, however, and some offer no advantages over older agents. Finally, all--including imipenem--are faced with increasing resistance of bacteria.


Subject(s)
Aztreonam/therapeutic use , Cephalosporins/therapeutic use , Imipenem/therapeutic use , Monobactams/therapeutic use , Thienamycins/therapeutic use , Aztreonam/pharmacology , Cephalosporins/pharmacology , Drug Resistance, Microbial , Humans , Imipenem/pharmacology
7.
Clin Infect Dis ; 20(2): 372-86, 1995 Feb.
Article in English | MEDLINE | ID: mdl-7742444

ABSTRACT

Thirty-two patients with subdural empyema at the University Hospital (Birmingham, AL) during the period from June 1970 through June 1992 were identified retrospectively. Clinical presentations of patients, methods of diagnosis, results of microbiological tests, types of therapy used, and outcomes of patients are presented and compared with those found in prior reports. The patients were separated into three groups based on the etiology of their disease: sinusitis, trauma and/or neurosurgery, and other miscellaneous causes. Sinusitis accounted for 56% of the cases; the predominant organisms isolated from these patients were anaerobes and streptococci. No cases occurred secondary to otitis media. The overall mortality rate was 9%; however, 55% of patients had neurological deficiency at the time they were discharged from the hospital. Factors that affected survival were age (P < .007) and level of consciousness at presentation (P < .008).


Subject(s)
Empyema, Subdural/diagnosis , Adolescent , Adult , Aged , Child , Child, Preschool , Craniocerebral Trauma/complications , Empyema, Subdural/etiology , Empyema, Subdural/therapy , Female , Humans , Infant , Male , Middle Aged , Postoperative Complications , Prognosis , Retrospective Studies , Sinusitis/complications
8.
N Engl J Med ; 330(25): 1792-6, 1994 Jun 23.
Article in English | MEDLINE | ID: mdl-8190157

ABSTRACT

BACKGROUND: Computer-based diagnostic systems are available commercially, but there has been limited evaluation of their performance. We assessed the diagnostic capabilities of four internal medicine diagnostic systems: Dxplain, Iliad, Meditel, and QMR. METHODS: Ten expert clinicians created a set of 105 diagnostically challenging clinical case summaries involving actual patients. Clinical data were entered into each program with the vocabulary provided by the program's developer. Each of the systems produced a ranked list of possible diagnoses for each patient, as did the group of experts. We calculated scores on several performance measures for each computer program. RESULTS: No single computer program scored better than the others on all performance measures. Among all cases and all programs, the proportion of correct diagnoses ranged from 0.52 to 0.71, and the mean proportion of relevant diagnoses ranged from 0.19 to 0.37. On average, less than half the diagnoses on the experts' original list of reasonable diagnoses were suggested by any of the programs. However, each program suggested an average of approximately two additional diagnoses per case that the experts found relevant but had not originally considered. CONCLUSIONS: The results provide a profile of the strengths and limitations of these computer programs. The programs should be used by physicians who can identify and use the relevant information and ignore the irrelevant information that can be produced.


Subject(s)
Diagnosis, Computer-Assisted/standards , Internal Medicine/standards , Software/standards , Analysis of Variance , Evaluation Studies as Topic , Humans
9.
JAMA ; 270(21): 2583-9, 1993 Dec 01.
Article in English | MEDLINE | ID: mdl-7901434

ABSTRACT

This document summarizes recommendations from a state-of-the-art conference convened to evaluate the role of nucleoside analogue reverse transcriptase inhibitors in the treatment of human immunodeficiency virus (HIV) infection. Data from controlled clinical trials of zidovudine, didanosine, and zalcitabine were reviewed by an expert panel, which then formulated guidelines to assist clinicians and HIV-infected patients in the use of these agents. Recommendations were framed in the context of clinical scenarios for patients with asymptomatic HIV infection who have not had prior antiretroviral therapy; those with signs and symptoms of HIV-related disease who have not received prior therapy; clinically stable patients who are tolerating initial zidovudine therapy; patients experiencing clinical progression while on zidovudine therapy; and those who are intolerant of antiretroviral therapy. The panel concluded that physicians need to integrate up-to-date scientific knowledge with other relevant needs to improve the care of HIV-infected patients.


Subject(s)
Dideoxynucleosides/standards , Dideoxynucleosides/therapeutic use , HIV Infections/drug therapy , Adult , CD4-Positive T-Lymphocytes , Clinical Trials as Topic , Didanosine/standards , Didanosine/therapeutic use , Drug Resistance , Guidelines as Topic , HIV Infections/immunology , Humans , Leukocyte Count , Zalcitabine/standards , Zalcitabine/therapeutic use , Zidovudine/standards , Zidovudine/therapeutic use
11.
Eur J Clin Microbiol Infect Dis ; 11(1): 55-8, 1992 Jan.
Article in English | MEDLINE | ID: mdl-1314175

ABSTRACT

Fluoroquinolones are variably active against methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-resistant Staphylococcus epidermidis (MRSE). The purpose of this study was to test the in vitro susceptibility of 50 isolates each of MRSA and MRSE to four of the new fluoroquinolones--sparfloxacin, ciprofloxacin, ofloxacin and norfloxacin--and to see if resistance could be induced in five susceptible strains of each species by serial passages with increasing concentrations of drug. A standard microdilution technique was used to determine minimal inhibitory concentrations (MICs) and minimal bactericidal concentrations (MBCs) of each drug for each isolate. Agar dilution plates were also prepared containing concentrations of drug varying from one-half of the reported MIC to 128 times the reported MIC, and microorganisms persisting were serially passaged. Initially, 98% of the strains of MRSA were susceptible to the fluoroquinolones. MBCs were essentially identical to MICs. Similarly, 96% of the strains of MRSE were susceptible. Following exposure to increasing concentrations of each fluoroquinolone, resistance appeared to emerge less rapidly to sparfloxacin and ofloxacin than to norfloxacin and ciprofloxacin.


Subject(s)
Anti-Infective Agents/pharmacology , Fluoroquinolones , Quinolones/pharmacology , Staphylococcus aureus/drug effects , Staphylococcus epidermidis/drug effects , Ciprofloxacin/pharmacology , Methicillin/pharmacology , Methicillin Resistance , Microbial Sensitivity Tests , Norfloxacin/pharmacology , Ofloxacin/pharmacology
12.
Eur J Clin Microbiol Infect Dis ; 10(7): 588-92, 1991 Jul.
Article in English | MEDLINE | ID: mdl-1655435

ABSTRACT

Cilofungin, a lipopeptide antifungal agent, was tested for in vitro activity alone and in combination with ketoconazole, itraconazole, flucytosine and amphotericin B against 102 clinical isolates of Candida species. At 48 hours all isolates of Candida albicans, Candida tropicalis, Candida paratropicalis and Candida glabrata were inhibited by less than or equal to 5 meg/ml of cilofungin. In contrast, the MIC90 for Candida krusei was 10 mcg/ml and for Candida parapsilosis greater than 40 mcg/ml. The interaction of combinations of cilofungin with amphotericin B, itraconazole, ketoconazole and flucytosine was additive or indifferent at 48 hours for 100%, 88%, 78% and 70% of all Candida species isolates, respectively. Overall, cilofungin demonstrated good activity in vitro against most Candida species isolates.


Subject(s)
Antifungal Agents/pharmacology , Candida/drug effects , Peptides, Cyclic , Amphotericin B/administration & dosage , Amphotericin B/pharmacology , Antifungal Agents/administration & dosage , Candida albicans/drug effects , Drug Therapy, Combination , Echinocandins , Flucytosine/administration & dosage , Flucytosine/pharmacology , Itraconazole , Ketoconazole/administration & dosage , Ketoconazole/analogs & derivatives , Ketoconazole/pharmacology , Microbial Sensitivity Tests , Peptides/administration & dosage , Peptides/pharmacology
13.
Antimicrob Agents Chemother ; 34(8): 1619-21, 1990 Aug.
Article in English | MEDLINE | ID: mdl-2221875

ABSTRACT

We compared the efficacies of cilofungin and amphotericin B treatment in a murine model of disseminated candidiasis. Three different dosages of each drug plus controls were evaluated. Statistically improved survival was noted only among mice treated with 1 mg of amphotericin B per kg of body weight (P less than 0.05). While all amphotericin B regimens and the two lower-dosage cilofungin regimens significantly reduced yeast cell counts in kidneys compared with the controls, the amphotericin B-treated mice had a significantly higher percentage of sterile kidneys following therapy compared with those treated with cilofungin (P = 0.0001).


Subject(s)
Amphotericin B/therapeutic use , Candidiasis/drug therapy , Peptides, Cyclic , Amphotericin B/blood , Animals , Echinocandins , Kidney/microbiology , Male , Mice , Organ Culture Techniques , Peptides/blood , Peptides/therapeutic use
14.
Infect Dis Clin North Am ; 3(3): 389-98, 1989 Sep.
Article in English | MEDLINE | ID: mdl-2671128

ABSTRACT

Antibiotics alone or in combination may either inhibit or kill bacteria. Laboratory methods are available to determine the activity of various antimicrobial agents and can aid the physician in selecting appropriate antimicrobial therapy for specific infectious disease disorders. A few infectious processes appear to require bactericidal antimicrobial therapy for cure. Additional multicenter trials of the ability of a standardized SBT to predict therapeutic outcome in specific bacterial diseases are required.


Subject(s)
Anti-Bacterial Agents/pharmacology , Bacteria/drug effects , Microbial Sensitivity Tests , Animals , Anti-Bacterial Agents/blood , Anti-Bacterial Agents/therapeutic use , Dogs , Drug Resistance, Microbial , Endocarditis, Bacterial/blood , Endocarditis, Bacterial/drug therapy , Humans , Meningitis/blood , Meningitis/drug therapy , Mice , Neutropenia/blood , Neutropenia/drug therapy , Osteomyelitis/blood , Osteomyelitis/drug therapy , Rabbits
15.
JAMA ; 262(2): 234-9, 1989 Jul 14.
Article in English | MEDLINE | ID: mdl-2544743

ABSTRACT

A total of 432 patients underwent brain biopsy for presumptive herpes simplex encephalitis. Three patient groups were identified. The first group, 195 patients (45%), had herpes simplex encephalitis confirmed by the isolation of herpes simplex virus from brain tissue at biopsy (193 patients) or autopsy (2 patients). The second group, 95 patients (22%), had diseases that were identified but that were not caused by herpes simplex virus. Three subgroups were recognized: (1) 38 patients (9%) with treatable disease, (2) 40 patients (9%) with nontreatable but diagnosed viral infection, and (3) 17 patients (4%) with identified diseases neither of viral etiology nor treatable. The third group, 142 patients (33%), remained without a diagnosis. Clinical presentation of patients in the second group was similar to that of those with herpes simplex encephalitis and those without a diagnosis. Patients in the subgroup with nontreatable but diagnosed viral infections had the greatest likelihood of returning to normal.


Subject(s)
Encephalitis/diagnosis , Herpes Simplex/diagnosis , Simplexvirus/isolation & purification , Adolescent , Age Factors , Biopsy , Brain/pathology , Consciousness , Diagnosis, Differential , Encephalitis/cerebrospinal fluid , Encephalitis/drug therapy , Encephalitis/mortality , Herpes Simplex/cerebrospinal fluid , Herpes Simplex/drug therapy , Herpes Simplex/mortality , Humans , Random Allocation
16.
20.
Am J Med Sci ; 292(2): 104-6, 1986 Aug.
Article in English | MEDLINE | ID: mdl-3728557

ABSTRACT

Q fever endocarditis, which is seen most often in Great Britain and Australia, has been rarely observed in the United States. A patient with an eight month febrile illness who had signs and symptoms of endocarditis and serologic studies diagnostic of Q fever endocarditis is reported. A history of extensive travel makes it unclear where he originally contracted the disease. Q fever endocarditis is probably underdiagnosed and should be looked for in any case of culture negative endocarditis or chronic fever of unknown origin.


Subject(s)
Endocarditis, Bacterial/etiology , Q Fever/complications , Aged , Anti-Bacterial Agents/therapeutic use , Antibodies, Bacterial/analysis , Coxiella/immunology , Endocarditis, Bacterial/drug therapy , Female , Fever of Unknown Origin/etiology , Humans , Male , Q Fever/drug therapy , United States
SELECTION OF CITATIONS
SEARCH DETAIL
...